162 related articles for article (PubMed ID: 35679661)
1. Metformin modulate immune fitness in hepatocellular carcinoma: Molecular and cellular approach.
Abd El-Fattah EE; Zakaria AY
Int Immunopharmacol; 2022 Aug; 109():108889. PubMed ID: 35679661
[TBL] [Abstract][Full Text] [Related]
2. Benzo[a]pyrene immunogenetics and immune archetype reprogramming of lung.
Abd El-Fattah EE; Abdelhamid AM
Toxicology; 2021 Nov; 463():152994. PubMed ID: 34678320
[TBL] [Abstract][Full Text] [Related]
3. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
Brown ZJ; Yu SJ; Heinrich B; Ma C; Fu Q; Sandhu M; Agdashian D; Zhang Q; Korangy F; Greten TF
Cancer Immunol Immunother; 2018 Aug; 67(8):1305-1315. PubMed ID: 29959458
[TBL] [Abstract][Full Text] [Related]
5. Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma.
Guo L; Li H; Fan T; Ma Y; Wang L
Life Sci; 2021 Aug; 279():119359. PubMed ID: 33753114
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.
Zheng L; Yang W; Wu F; Wang C; Yu L; Tang L; Qiu B; Li Y; Guo L; Wu M; Feng G; Zou D; Wang H
Clin Cancer Res; 2013 Oct; 19(19):5372-80. PubMed ID: 23942093
[TBL] [Abstract][Full Text] [Related]
7. Metformin exhibits antineoplastic effects on Pten-deficient endometrial cancer by interfering with TGF-β and p38/ERK MAPK signalling.
Ruiz-Mitjana A; Vidal-Sabanés M; Navaridas R; Perramon-Güell A; Yeramian A; Nicholson-Sabaté N; Egea J; Encinas M; Matias-Guiu X; Dolcet X
Biomed Pharmacother; 2023 Dec; 168():115817. PubMed ID: 37925934
[TBL] [Abstract][Full Text] [Related]
8. GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma.
Wang Z; He L; Li W; Xu C; Zhang J; Wang D; Dou K; Zhuang R; Jin B; Zhang W; Hao Q; Zhang K; Zhang W; Wang S; Gao Y; Gu J; Shang L; Tan Z; Su H; Zhang Y; Zhang C; Li M
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34489334
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses.
Zhang HH; Mei MH; Fei R; Liu F; Wang JH; Liao WJ; Qin LL; Wei L; Chen HS
J Viral Hepat; 2010 Mar; 17 Suppl 1():34-43. PubMed ID: 20586932
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.
Lu Z; Zuo B; Jing R; Gao X; Rao Q; Liu Z; Qi H; Guo H; Yin H
J Hepatol; 2017 Oct; 67(4):739-748. PubMed ID: 28549917
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma.
Liu X; Ren H; Guo H; Wang W; Zhao N
Clin Exp Immunol; 2021 Feb; 203(2):219-229. PubMed ID: 33030251
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment.
Granito A; Muratori L; Lalanne C; Quarneti C; Ferri S; Guidi M; Lenzi M; Muratori P
World J Gastroenterol; 2021 Jun; 27(22):2994-3009. PubMed ID: 34168403
[TBL] [Abstract][Full Text] [Related]
13. Asarone and metformin delays experimentally induced hepatocellular carcinoma in diabetic milieu.
Das BK; Choukimath SM; Gadad PC
Life Sci; 2019 Aug; 230():10-18. PubMed ID: 31121175
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the
Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
16. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
17. Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma.
Chen L; Zhou S; Qin J; Hu H; Ma H; Liu B; Wang X; Ma J; Ye S; Zhong C; Zhou G; Liang C
Mol Cancer; 2013 Dec; 12(1):153. PubMed ID: 24304581
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma.
Chen J; Gingold JA; Su X
Trends Mol Med; 2019 Nov; 25(11):1010-1023. PubMed ID: 31353124
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol and Immune Microenvironment: Path Towards Tumorigenesis.
Saad EE; Michel R; Borahay MA
Curr Nutr Rep; 2024 May; ():. PubMed ID: 38696074
[TBL] [Abstract][Full Text] [Related]
20. Recent Insights of Metformin on Hepatocellular Carcinoma (HCC).
Wang K; Zhang K; Zhang X; Chen D; Jiang S
Mini Rev Med Chem; 2023; 23(11):1154-1166. PubMed ID: 35747976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
